Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients

被引:10
作者
Dean, N. R. [1 ]
Sweeny, L. [1 ]
Harari, P. M. [3 ]
Bonner, J. A. [2 ]
Jones, V. [1 ]
Clemons, L. [1 ]
Geye, H. [3 ]
Rosenthal, E. L. [1 ]
机构
[1] Univ Alabama, Dept Surg, Div Otolaryngol, Birmingham, AL 35294 USA
[2] Univ Alabama, Dept Med, Birmingham, AL 35294 USA
[3] Univ Wisconsin, Dept Human Oncol, Madison, WI USA
关键词
Erbitux; cetuximab; neck dissection; head and neck cancer; radiation; EGFR; EPIDERMAL-GROWTH-FACTOR; METASTATIC COLORECTAL-CANCER; SQUAMOUS-CELL CARCINOMA; KERATINOCYTE MIGRATION; PLUS CETUXIMAB; PHASE-II; COMPLICATIONS; CHEMOTHERAPY; RADIOTHERAPY; BEVACIZUMAB;
D O I
10.12968/jowc.2011.20.4.166
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: This study set out to determine if cetuximab treatment increases the risk of wound healing complications when combined with radiation therapy. Method: We performed a retrospective chart review of head and neck cancer patients who received salvage neck dissections between 1999 and 2007, at two academic tertiary care centres. Complications from wound healing were compared between radiation and combined therapy groups. Results:A total of 35 patients received radiation (n=20) or combined radiation and cetuximab therapy (n=15) prior to neck dissection. The treatment groups were similar in regard to demographic and primary tumour-related characteristics. The time between treatment and salvage neck dissection did not differ between the radiation (3.9 months) and combination treatment (3.0 months) groups (p=0.15). Wound healing complications occurred in 13% (2/15) of the patients treated with radiation and cetuximab and there were no complications in patients who received radiation alone (p=0.20). Conclusion: Cetuximab did not significantly increase the risk of post-surgical wound complications, although a higher absolute number of wound complications was observed in the group treated with cetuximab and radiation therapy, compared with the group treated with radiation alone. Conflict of interest: This work was supported by a grant from the National Institute of Health (2T32 CA091078-06). One of the authors, JAB, is an occasional consultant and honoraria for ImClone and Bristol-Meyers Squibb.
引用
收藏
页码:166 / 170
页数:5
相关论文
共 20 条
[1]   EPIDERMAL GROWTH-FACTOR AND INSULIN-LIKE GROWTH FACTOR-I ENHANCE KERATINOCYTE MIGRATION [J].
ANDO, Y ;
JENSEN, PJ .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1993, 100 (05) :633-639
[2]   Growth factors and cytokines in wound healing [J].
Barrientos, Stephan ;
Stojadinovic, Olivera ;
Golinko, Michael S. ;
Brem, Harold ;
Tomic-Canic, Marjana .
WOUND REPAIR AND REGENERATION, 2008, 16 (05) :585-601
[3]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[4]  
Boyd TS, 1998, HEAD NECK-J SCI SPEC, V20, P132, DOI 10.1002/(SICI)1097-0347(199803)20:2<132::AID-HED6>3.0.CO
[5]  
2-3
[6]   RISK-FACTORS FOR COMPLICATIONS IN CLEAN-CONTAMINATED HEAD AND NECK SURGICAL-PROCEDURES [J].
GIROD, DA ;
MCCULLOCH, TM ;
TSUE, TT ;
WEYMULLER, EA .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1995, 17 (01) :7-13
[7]   Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer [J].
Hanna, Nasser ;
Lilenbaum, Rogerio ;
Ansari, Rafat ;
Lynch, Thomas ;
Govindan, Ramaswamy ;
Jaenne, Pasi A. ;
Bonomi, Philip .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (33) :5253-5258
[8]  
Hurwitz H, 2006, SEMIN ONCOL, V33, pS26, DOI 10.1053/j.seminoncol.2006.08.001
[9]   GROWTH-STIMULATION OF A431 CELLS BY EPIDERMAL GROWTH-FACTOR - IDENTIFICATION OF HIGH-AFFINITY RECEPTORS FOR EPIDERMAL GROWTH-FACTOR BY AN ANTI-RECEPTOR MONOCLONAL-ANTIBODY [J].
KAWAMOTO, T ;
SATO, JD ;
LE, A ;
POLIKOFF, J ;
SATO, GH ;
MENDELSOHN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (05) :1337-1341
[10]   Randomized phase II - study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer - PARC: study protocol [ISRCTN56652283] [J].
Krempien, R ;
Muenter, MW ;
Huber, PE ;
Nill, S ;
Friess, H ;
Timke, C ;
Didinger, B ;
Buechler, P ;
Heeger, S ;
Herfarth, KK ;
Abdollahi, A ;
Buchler, MW ;
Debus, J .
BMC CANCER, 2005, 5 (1)